title: Low-dose intravenous cyclophosphamide in systemic sclerosis: an open prospective efficacy study in patients with early diffuse disease.
abstract: OBJECTIVE
  To investigate the efficacy of a treatment with low-dose intravenous cyclophosphamide (CYC) and low-dose prednisone in early diffuse cutaneous systemic sclerosis (dcSSc).
  
  
  METHODS
  Patients with dcSSc and a disease duration <24 months consecutively admitted to a tertiary centre underwent a prospective 1-year study. They were treated with i.v. CYC 500 mg/pulses, 10 mg prednisone equivalent, and supportive therapy. Modified Rodnan skin score (mRss), Health Assessment Questionnaire-Disability Index (HAQ-DI), forced vital capacity (FVC), and diffusing lung capacity for CO (DLCO) were assessed as outcome measures. In addition, the nine Medsger severity scale scores were evaluated.
  
  
  RESULTS
  mRss and DLCO significantly improved at both 6 (p = 0.002 and 0.012, respectively) and 12 months (p = 0.002 and 0.003, respectively). HAQ-DI showed a nearly significant reduction at 12 months (p = 0.06). Medsger's severity scores also improved for general condition (p = 0.001), peripheral vascular (p = 0.05), skin (p = 0.02), joint/tendon (p = 0.001), muscle (p = 0.05), and lung (p = 0.02). No treatment interruption was needed.
  
  
  CONCLUSIONS
  This preliminary study suggests a role for low-dose i.v. CYC in the treatment of early dcSSc. Controlled studies are warranted.
authors.affiliation: The Rheumatology Health Unit, Second University of Naples, Italy. gabriele.valentini@unina2.it
authors.forename: G
authors.initials: G
authors.lastname: Valentini
authors.forename: C
authors.initials: C
authors.lastname: Paone
authors.forename: G
authors.initials: G
authors.lastname: La Montagna
authors.forename: I
authors.initials: I
authors.lastname: Chiarolanza
authors.forename: M
authors.initials: M
authors.lastname: Menegozzo
authors.forename: E
authors.initials: E
authors.lastname: Colutta
authors.forename: L
authors.initials: L
authors.lastname: Ruocco
mesh_terms: D000328:Adult; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D018579:Patient Selection; D011241:Prednisone / Q000627:therapeutic use; D045743:Scleroderma, Diffuse / Q000188:drug therapy / Q000276:immunology; D012595:Scleroderma, Systemic / Q000188:drug therapy* / Q000276:immunology; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents; D003520:Cyclophosphamide; D011241:Prednisone